Entrada Therapeutics (NASDAQ:TRDA – Free Report) had its price objective reduced by HC Wainwright from $25.00 to $20.00 in a research report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Entrada Therapeutics Stock Performance Shares of NASDAQ:TRDA opened at $12.97 on Monday. The firm has a market capitalization […]
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such.
NEW YORK, Nov. 29, 2023 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. . Such investors are advised to contact Robert S. Willoughby at.